An alternative approach is to utilize nonsecosteroidal VDR agonists that are not predicted to be substrates for CYP24A1 metabolism and show greater discrimination between levels required to induce a desired biological response and those that induce hypercalcemia. Here, VDR is linked to hypercalcemia disease.